The Gaithersburg-based company is raising $5 million, ahead of a planned Series A round of at least $30 million in the first quarter of 2019, to bring a therapy for drug-resistant bacteria to market as soon as possible.
{iframe}https://www.bizjournals.com/washington/news/2018/06/14/fighting-fire-with-fire-how-a-gaithersburg-company.html{/iframe}